Literature DB >> 16274517

French-Canadian linguistic validation of the NIH Chronic Prostatitis Symptom Index.

P I Karakiewicz1, P Perrotte, L Valiquette, F Benard, M McCormack, C Menard, M McNaughton Collins, J C Nickel.   

Abstract

INTRODUCTION: The NIH Chronic Prostatitis Symptom Index (CPSI) is recommended in the clinical evaluation of men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). However, its use is not possible in French speakers, as it has not been validated in this population. We performed a linguistic validation of the CPSI.
METHODS: Linguistic translation followed the forward-backward-forward technique and relied on professional medical translators, bilingual health professionals, and patient input. Along with the SF-12, the translated version was administered to a convenience sample of men presenting for pre-vasectomy visits (controls) and to consecutive patients with established CP/CPPS (cases). Men with CP/CPPS were subsequently asked to complete a 14-day retest questionnaire. Psychometric testing addressed standard reliability and validity characteristics.
RESULTS: Thirty-six cases and 38 controls with respective mean ages of 46.5 and 44.0 years participated and 33 (91.2%) cases completed the retest questionnaire. Pain (p<0.001), urinary (p<0.001) and quality-of-life (QOL) scale (p<0.001) score means differed between cases and controls. For the same scales, Cronbach's alphas for cases were respectively 0.70, 0.72 and 0.79 versus 0.80, 0.57, and 0.88 for controls. The retest product-moments were 0.83 for pain, 0.55 for urinary, and 0.83 for QOL scales. In cases, strong correlation was noted between QOL and pain scales (r=0.7), and between urinary and pain scales (r=0.6), versus moderate correlation between QOL and urinary scales (r=0.4). Negative correlation was recorded between CPSI scales and SF-12 scales, which ranged from -0.2 to -0.4.
CONCLUSIONS: When applied to CPPS and control subjects, the French Canadian CPSI translation demonstrates excellent discriminant properties. Moreover, its reliability and validity characteristics confirm the qualities of the CPSI as a standard evaluative tool for men with CPPS.

Entities:  

Mesh:

Year:  2005        PMID: 16274517

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  4 in total

1.  Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies.

Authors:  J Curtis Nickel; Richard B Alexander; Rodney Anderson; Richard Berger; Craig V Comiter; Nand S Datta; Jackson E Fowler; John N Krieger; J Richard Landis; Mark S Litwin; Mary McNaughton-Collins; Michael P O'Leary; Michel A Pontari; Anthony J Schaeffer; Daniel A Shoskes; Paige White; John Kusek; Leroy Nyberg
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 2.  Epidemiology of prostatitis.

Authors:  John N Krieger; Shaun Wen Huey Lee; Jeonseong Jeon; Phaik Yeong Cheah; Men Long Liong; Donald E Riley
Journal:  Int J Antimicrob Agents       Date:  2007-12-31       Impact factor: 5.283

Review 3.  A systematic review of cross-cultural adaptation of the National Institutes of Health Chronic Prostatitis Symptom Index.

Authors:  Rong-Liang Dun; Jennifer Tsai; Xiao-Hua Hu; Jian-Min Mao; Wen-Jing Zhu; Guang-Chong Qi; Yu Peng
Journal:  Health Qual Life Outcomes       Date:  2021-05-31       Impact factor: 3.186

4.  Rescoring the NIH chronic prostatitis symptom index: nothing new.

Authors:  J Q Clemens; E A Calhoun; M S Litwin; M McNaughton-Collins; R L Dunn; E M Crowley; J R Landis
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-06-02       Impact factor: 5.554

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.